Most patients with Guillain-Barre recover within 2 months to 1 year and their survival time is not affected; however, patients over 60 years of age with rapidly progressive disease requiring assisted breathing usually have a poor prognosis and their survival may be relatively shortened. Guillain-Barre is an autoimmune-mediated peripheral neuropathy, characterized by an acute onset of symptoms that peaks in about two weeks, manifested by delayed muscle weakness in the extremities, which may be accompanied by abnormal sensations such as burning, numbness, and tingling in the extremities, with a glove-glove-like distribution; some patients may have autonomic dysfunction such as skin flushing and increased sweating. Most patients can be cured and survive for a long time if standardized treatment is carried out in time. However, if the lesion involves the respiratory muscles and is not treated in time, it can be fatal. The treatment of Guillain-Barre is divided into general treatment: anti-infection, respiratory management, nutritional support and symptomatic treatment; immunotherapy: plasma replacement, immunoglobulin intravenous treatment; in addition, early formal neurorehabilitation exercise treatment is required.